[pubmed] Neuro-ophthalmic Complications of Immune-Checkpoint Inhibitors

[RSS-Bot]

Semin Ophthalmol. 2021 Feb 27:1-9. doi: 10.1080/08820538.2021.1890796. Online ahead of print.

ABSTRACT

Immune checkpoint inhibitors (ICIs) have revolutionized the field of oncology by modulating the immune cell-cancer cell interaction and thereby promoting immune system disinhibition in order to target several types of malignancies. There are three classes of immune checkpoint inhibitors (ICIs): anti-cytotoxic T-lymphocyte associated antigen 4 (CTLA-4), anti-programmed cell death protein-1 (PD-1), and anti-programmed cell death ligand-1 (PD-L1).It is not uncommon for physicians across all specialties to encounter a patient with a history of malignancy and ICI exposure, necessitating familiarity with their potential complications. In this review article, we discuss the most common immune-related adverse events (irAEs) pertaining to the central and peripheral nervous systems and their potential afferent and efferent neuro-ophthalmic manifestations. Early recognition and treatment of these irAEs, and discontinuation of the offending ICI are all critical steps to prevent morbidity and mortality.

PMID:33641589 | DOI:10.1080/08820538.2021.1890796


Source: https://pubmed.ncbi.nlm.nih.gov/3364158 ... 0&v=2.14.2